Teriparatide is a recombinant peptide commercialized by Entera Bio, with a leading Phase II program in Hypoparathyroidism. According to Globaldata, it is involved in 5 clinical trials, of which 3 were completed, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Teriparatide’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Teriparatide is expected to reach an annual total of $26 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
EB-612 is under development for the treatment of hypoparathyroidism. The drug candidate is administered orally in the form of tablet. PTH (1-34) is a regulator of calcium levels in the blood. The drug candidate is developed based on technology that works by protecting and stabilizing orally active peptides from the harsh chemical environment of stomach while in passage through the gastrointestinal tract thereby promoting their absorption.
Entera Bio Overview
Entera Bio is a biopharmaceutical company that specializes in the oral delivery of molecules and biologics. The company develops novel drug delivery platforms for oral delivery of large molecule protein active pharmaceutical ingredients. It offers product candidates such as EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Its other pipeline products include GLP-2 for short bowel syndrome and hGH for GH deficiency. Entera Bio conducts clinical trials on its proprietary technology which allows oral delivery of large molecules and biologics while enhancing their absorption in the gastrointestinal tract. The company also provides treatment for bone healing. It operates in Israel and the US. Entera Bio is headquartered in Jerusalem, Israel.
The company reported revenues of (US Dollars) US$0.6 million for the fiscal year ended December 2021 (FY2021), an increase of 56.4% over FY2020. The operating loss of the company was US$12.2 million in FY2021, compared to an operating loss of US$11.2 million in FY2020. The net loss of the company was US$12.2 million in FY2021, compared to a net loss of US$11.2 million in FY2020.
For a complete picture of Teriparatide’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.